Key Highlights
- Panacea Biotec receives UNICEF Letter of Award to supply bivalent oral polio vaccine (bOPV).
- Long-term agreement runs from 1 April 2026 to 31 March 2030.
- The quoted contract value is ~US$ 35.65 million (approximately ₹315 crore) and pertains to supply scheduled for Q2 CY2026 and CY2027.
- Supply will be in 10- and 20-vial presentations of bOPV.
- The award is international and not a related-party transaction.
Panacea Biotec Limited has announced that it has received a Letter of Award from UNICEF for a long-term agreement to supply bivalent oral polio vaccine (bOPV). The contract, valued at approximately US$ 35.65 million (around ₹315 crore), is linked to supply during the second quarter of calendar year 2026 (Q2 CY2026) and CY2027.
The agreement will run from April 1, 2026, to March 31, 2030. Under this arrangement, Panacea Biotec will provide bOPV in 10- and 20-vial presentations. UNICEF, as part of its procurement transparency, will publish supplier details, vaccine presentations, award value, and annual pricing on its official website.
The order has been awarded by an international entity and does not involve any related-party transactions. Panacea Biotec noted that this award further strengthens its position in supporting global immunization programs.
Panacea Biotec is an Indian biotechnology and pharmaceutical company engaged in the research, development, and manufacturing of vaccines and pharmaceutical formulations. Its portfolio spans therapeutic areas such as vaccines, diabetes, oncology, pain management, and transplant medicine.